BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 24568508)

  • 1. Hybrid capture 2 assay based evaluation of high-risk HPV status in healthy women of north-east India.
    Rai AK; Das D; Kataki AC; Barmon D; Aggarwal D; Deka P; Shrivastava S; Sharma JD; Sarma A; Baruah U; Sharma M
    Asian Pac J Cancer Prev; 2014; 15(2):861-5. PubMed ID: 24568508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Agreement between the AMPLICOR Human Papillomavirus Test and the Hybrid Capture 2 assay in detection of high-risk human papillomavirus and diagnosis of biopsy-confirmed high-grade cervical disease.
    Carozzi F; Bisanzi S; Sani C; Zappa M; Cecchini S; Ciatto S; Confortini M
    J Clin Microbiol; 2007 Feb; 45(2):364-9. PubMed ID: 17122008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany--experience over 3 years.
    Luyten A; Scherbring S; Reinecke-Lüthge A; Braun BE; Pietralla M; Theiler K; Petry KU
    J Clin Virol; 2009 Nov; 46 Suppl 3():S5-10. PubMed ID: 20129072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary cervical cancer screening and triage using an mRNA human papillomavirus assay and visual inspection.
    Nieves L; Enerson CL; Belinson S; Brainard J; Chiesa-Vottero A; Nagore N; Booth C; Pérez AG; Chávez-Avilés MN; Belinson J
    Int J Gynecol Cancer; 2013 Mar; 23(3):513-8. PubMed ID: 23334437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of the diagnostic accuracy of testing for high-risk (HR) human papillomavirus (HPV) types 16, 18 and 45 in precancerous cervical lesions: preliminary data.
    Tiews S; Steinberg W; Schneider W; Hanrath C
    J Clin Virol; 2009 Nov; 46 Suppl 3():S11-5. PubMed ID: 20129068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Fast Transfer Analysis Cartridges for Cervical Sampling and Real Time PCR Based High Risk HPV Testing in Cervical Cancer Prevention - a Feasibility Study from South India.
    Vijayalakshmi R; Viveka TS; Malliga JS; Murugan K; Kanchana A; Arvind K
    Asian Pac J Cancer Prev; 2015; 16(14):5993-9. PubMed ID: 26320486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of high-risk human papillomavirus testing in patients with low-grade squamous intraepithelial lesions.
    Levi AW; Harigopal M; Hui P; Schofield K; Chhieng DC
    Cancer Cytopathol; 2011 Aug; 119(4):228-34. PubMed ID: 21732551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of HPV DNA testing with hybrid capture 2 in triaging women with minor cervical cytologic abnormalities (ASC-US/LSIL) in Northern Thailand.
    Khunamornpong S; Settakorn J; Sukpan K; Srisomboon J; Suprasert P; Siriaunkgul S
    Asian Pac J Cancer Prev; 2014; 15(24):10961-6. PubMed ID: 25605209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HPV Prevalence in the Dutch cervical cancer screening population (DuSC study): HPV testing using automated HC2, cobas and Aptima workflows.
    Huijsmans CJ; Geurts-Giele WR; Leeijen C; Hazenberg HL; van Beek J; de Wild C; van der Linden JC; van den Brule AJ
    BMC Cancer; 2016 Nov; 16(1):922. PubMed ID: 27894291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can human papillomavirus DNA testing of self-collected vaginal samples compare with physician-collected cervical samples and cytology for cervical cancer screening in developing countries?
    Bhatla N; Dar L; Patro AR; Kumar P; Kriplani A; Gulati A; Iyer VK; Mathur SR; Sreenivas V; Shah KV; Gravitt PE
    Cancer Epidemiol; 2009 Dec; 33(6):446-50. PubMed ID: 19931499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Menstrual pad, a cervical cancer screening tool, a population-based study in rural India.
    Budukh A; Palayekar V; Maheshwari A; Deodhar K; Purwar P; Bagal S; Vadigoppula A; Lokhande M; Panse N; Dikshit R; Badwe R
    Eur J Cancer Prev; 2018 Nov; 27(6):546-552. PubMed ID: 28704213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analytical evaluation of the PapilloCheck test, a new commercial DNA chip for detection and genotyping of human papillomavirus.
    Dalstein V; Merlin S; Bali C; Saunier M; Dachez R; Ronsin C
    J Virol Methods; 2009 Mar; 156(1-2):77-83. PubMed ID: 19041893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human telomerase gene and high-risk human papillomavirus infection are related to cervical intraepithelial neoplasia.
    Zhao XY; Cui Y; Jiang SF; Liu KJ; Han HQ; Liu XS; Li Y
    Asian Pac J Cancer Prev; 2015; 16(2):693-7. PubMed ID: 25684510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the hybrid capture II assay with the human papillomavirus DNA chip test for the detection of high-grade cervical lesions.
    Kang WD; Kim CH; Cho MK; Kim JW; Kim YH; Choi HS; Kim SM
    Int J Gynecol Cancer; 2009 Jul; 19(5):924-8. PubMed ID: 19574786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the AMPLICOR human papillomavirus test and the hybrid capture 2 assay for detection of high-risk human papillomavirus in women with abnormal PAP smear.
    De Francesco MA; Gargiulo F; Schreiber C; Ciravolo G; Salinaro F; Manca N
    J Virol Methods; 2008 Jan; 147(1):10-7. PubMed ID: 17854914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A study of genotyping for management of human papillomavirus-positive, cytology-negative cervical screening results.
    Schiffman M; Burk RD; Boyle S; Raine-Bennett T; Katki HA; Gage JC; Wentzensen N; Kornegay JR; Aldrich C; Tam T; Erlich H; Apple R; Befano B; Castle PE
    J Clin Microbiol; 2015 Jan; 53(1):52-9. PubMed ID: 25339396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of type-specific human papillomavirus infection among women in France: Implications for screening, vaccination, and a future generation of multivalent HPV vaccines.
    Monsonego J; Zerat L; Syrjänen K; Zerat JC; Smith JS; Halfon P
    Vaccine; 2012 Jul; 30(35):5215-21. PubMed ID: 22713720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distribution of human papilloma virus infections of uterine cervix among women of reproductive age--a cross sectional hospital-based study from North East India.
    Sarma U; Mahanta J; Borkakoty B; Sarmah B
    Asian Pac J Cancer Prev; 2015; 16(4):1519-23. PubMed ID: 25743824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-risk human papillomavirus genotype distribution and attribution to cervical cancer and precancerous lesions in a rural Chinese population.
    Zhao XL; Hu SY; Zhang Q; Dong L; Feng RM; Han R; Zhao FH
    J Gynecol Oncol; 2017 Jul; 28(4):e30. PubMed ID: 28541628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.